All Stories

  1. Treatment and prevention of epilepsy in onchocerciasis-endemic areas is urgently needed
  2. Methodological challenges for conducting case-control studies to investigate the association between onchocerciasis and epilepsy including nodding syndrome
  3. Onchocerciasis-associated epilepsy: an explorative case-control study with viral metagenomic analyses on Onchocerca volvulus
  4. Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent infection in the Bono Region of Ghana: a mixed-methods study
  5. Accessibility to formal education among persons with epilepsy in Mahenge, Tanzania
  6. Persistence of onchocerciasis and associated dermatologic and ophthalmic pathologies after 27 years of ivermectin mass drug administration in the middle belt of Ghana
  7. Procedure for Handling and Storage of Onchocerca volvulus Microfilariae Obtained from Skin Snips for Downstream Genetic Work
  8. Disability assessment among persons with epilepsy in Mahenge, an onchocerciasis-endemic area in Tanzania: A cross-sectional study
  9. The onchocerciasis hypothesis of nodding syndrome
  10. Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27 years of mass drug administration with ivermectin
  11. Mortality among persons with epilepsy in onchocerciasis-endemic and non-endemic areas of sub-Saharan Africa: A systematic review and meta-analysis
  12. Quality of life of persons with epilepsy in Mahenge, an onchocerciasis-endemic area in Tanzania: A cross-sectional study
  13. Assessing Onchocerca volvulus Intensity of Infection and Genetic Diversity Using Mitochondrial Genome Sequencing of Single Microfilariae Obtained before and after Ivermectin Treatment
  14. Impact of a bi-annual community-directed treatment with ivermectin programme on the incidence of epilepsy in an onchocerciasis-endemic area of Mahenge, Tanzania: A population-based prospective study
  15. Nodding syndrome, a case-control study in Mahenge, Tanzania: Onchocerca volvulus and not Mansonella perstans as a risk factor
  16. Onchocerciasis-associated epilepsy in Maridi, South Sudan: Modelling and exploring the impact of control measures against river blindness
  18. Case definitions for onchocerciasis-associated epilepsy and nodding syndrome: A focused review
  19. Onchocerciasis-associated epilepsy: an update and future perspectives
  20. How to decrease the epilepsy disease burden in sub-Saharan Africa?
  21. Nodding Syndrome: Clinical Characteristics, Risks Factors, Access to Treatment, and Perceptions in the Greater Mundri Area, South Sudan
  22. Impact of COVID-19 on the well-being of children with epilepsy including nodding syndrome in Uganda: A qualitative study
  23. Nodding syndrome, populations at risk need to be aware this is a preventable condition
  24. Nodding Syndrome, a Case-control Study in Mahenge, Tanzania: <em>Onchocerca volvulus </em>and not <em>Mansonella </em><em>perstans</em> as Risk Factor
  25. COVID-19 in Low and Middle Income Countries
  26. Adherence to COVID-19 preventive measures in Sub-Saharan Africa during the 1st year of the pandemic: Pooled analysis of the International Citizen Project on COVID-19 (ICPCovid) surveys
  27. New vector of River blindness identified in Africa
  28. High Prevalence of Glaucoma among Patients in an Onchocerciasis Endemic Area (Mahenge, Tanzania)
  29. Enhanced surveillance of monkeypox in Bas-Uélé, Democratic Republic of Congo: the limitations of symptom-based case definitions
  30. Infectious Diseases Institute at Makerere University College of Health Sciences: a case study of a sustainable capacity building model for health care, research and training
  31. Community Knowledge, Attitudes and Practices Regarding Onchocerciasis in Rural Villages With a High Epilepsy Prevalence in Mahenge, Tanzania: A Qualitative Study
  32. Correction: Dusabimana et al. Surveillance for Onchocerciasis-Associated Epilepsy and Ov16 IgG4 Testing of Children 6–10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening. Pathogens 2022, 11, 281
  33. Immunoinformatics Design and Assessment of a Multiepitope Antigen (OvMCBL02) for Onchocerciasis Diagnosis and Monitoring
  34. Enhanced surveillance of monkeypox in Bas-Uélé, Democratic Republic of Congo: the limitations of symptom-based case definitions
  35. ‘There Were Moments We Wished She Could Just Die’: The Highly Gendered Burden of Nodding Syndrome in Northern Uganda
  36. Psychosocial Factors Associated With Adherence to COVID-19 Preventive Measures in Low-Middle- Income Countries, December 2020 to February 2021
  37. High COVID-19 Vaccine Acceptance among Eye Healthcare Workers in Uganda
  38. Ivermectin for malaria control in mass drug administration programmes
  39. The Prevalence of Onchocerciasis-Associated Epilepsy in Mundri West and East Counties, South Sudan: A Door-to-Door Survey
  40. Defining post-COVID condition
  41. Reducing onchocerciasis-associated morbidity in onchocerciasis-endemic foci with high ongoing transmission: a focus on the children.
  42. Community knowledge, attitudes, and practices regarding epilepsy in Mahenge, Tanzania: A socio-anthropological study in an onchocerciasis-endemic area with a high prevalence of epilepsy
  43. Impact of the COVID-19 pandemic on persons with epilepsy in Uganda: A descriptive cross-sectional study
  44. Using Andersen’s model of health care utilization to assess factors associated with COVID-19 testing among adults in nine low-and middle-income countries: an online survey
  45. Surveillance for Onchocerciasis-Associated Epilepsy and OV16 IgG4 Testing of Children 6–10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening
  46. The Prevalence of Onchocerciasis-Associated Epilepsy in Mundri West and East Counties, South Sudan: A Door to Door Survey
  47. Community perception of epilepsy and its treatment in onchocerciasis-endemic villages of Maridi county, western equatoria state, South Sudan
  48. Adherence to COVID-19 Preventive Measures among Dental Care Workers in Vietnam: An Online Cross-Sectional Survey
  49. Prevalence and Risk Factors Associated with Epilepsy in Six Health Districts of Mali: A Community-Based Cross-Sectional and Nested Case-Control Study
  50. Cardiovascular risk factors and clinical outcomes of patients hospitalized with COVID-19 pneumonia in Somalia
  51. Adults’ Acceptance of COVID-19 Vaccine for Children in Selected Lower- and Middle-Income Countries
  52. Adherence to COVID-19 preventive measures among dental care workers in Vietnam: an online cross-sectional survey
  53. Treatment of Pregnant Women with Ivermectin during Mass Drug Distribution: Time to Investigate Its Safety and Potential Benefits
  54. Tandem Use of OvMANE1 and Ov-16 ELISA Tests Increases the Sensitivity for the Diagnosis of Human Onchocerciasis
  55. Risk Factors for Nodding Syndrome and Other Forms of Epilepsy in Northern Uganda: A Case-Control Study
  56. Onchocerca volvulus transmission in the Mbam valley of Cameroon following 16 years of annual community-directed treatment with ivermectin, and the description of a new cytotype of Simulium squamosum
  57. A peer support group intervention to decrease epilepsy-related stigma in an onchocerciasis-endemic area in Mahenge, Tanzania: A pilot study
  58. “Slash and Clear”, a Community-Based Vector Control Method to Reduce Onchocerciasis Transmission by Simulium sirbanum in Maridi, South Sudan: A Prospective Study
  59. Association Between Ov16 Seropositivity and Neurocognitive Performance Among Children in Rural Cameroon: a Pilot Study
  60. Ivermectin Should Not Be Recommended to Treat Severe Acute Respiratory Syndrome 2 Infection
  61. ‘Slash and clear’ vector control for onchocerciasis elimination and epilepsy prevention: a protocol of a cluster randomised trial in Cameroonian villages
  62. Epilepsy in the Sanaga‐Mbam valley, an onchocerciasis‐endemic region in Cameroon: electroclinical and neuropsychological findings
  63. COVID-19 Vaccine Acceptability and Its Determinants in Mozambique: An Online Survey
  64. Fear and depression during the COVID-19 outbreak in Cameroon: a nation-wide observational study
  65. Stress and Associated Factors among Frontline Healthcare Workers in the COVID-19 Epicenter of Da Nang City, Vietnam
  66. No Evidence for the Involvement of Leiomodin-1 Antibodies in the Pathogenesis of Onchocerciasis-Associated Epilepsy
  67. Extensive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Associated With Low Mortality in Kinshasa, Democratic Republic of the Congo: For How Long?
  68. No Evidence Known Viruses Play a Role in the Pathogenesis of Onchocerciasis-Associated Epilepsy. An Explorative Metagenomic Case-Control Study
  69. COVID-19 Vaccine Acceptance in Azuay Province, Ecuador: A Cross-Sectional Online Survey
  70. First description of Nodding Syndrome in the Central African Republic
  71. Impact of COVID-19 on Healthcare Workers in Brazil between August and November 2020: A Cross-Sectional Survey
  72. Serotonin Levels in the Serum of Persons with Onchocerciasis-Associated Epilepsy: A Case-Control Study
  73. COVID-19 Vaccine Acceptability and Adherence to Preventive Measures in Somalia: Results of an Online Survey
  74. Stress and associated factors among frontline healthcare workers in the COVID-19 epicenter of Da Nang city, Vietnam
  75. Factors Affecting COVID-19 Vaccine Acceptance: An International Survey among Low- and Middle-Income Countries
  76. The World Health Organization road map for neglected tropical diseases 2021–2030: implications for onchocerciasis elimination programs
  77. High Prevalence of Epilepsy in an Onchocerciasis-Endemic Area in Mvolo County, South Sudan: A Door-To-Door Survey
  78. Intimate Partners Violence against Women during a COVID-19 Lockdown Period: Results of an Online Survey in 7 Provinces of the Democratic Republic of Congo
  79. Well-Being of Healthcare Workers and the General Public during the COVID-19 Pandemic in Vietnam: An Online Survey
  80. The Secretome of Filarial Nematodes and Its Role in Host-Parasite Interactions and Pathogenicity in Onchocerciasis-Associated Epilepsy
  81. Follow-Up Survey of the Impact of COVID-19 on People Living with HIV during the Second Semester of the Pandemic
  82. Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study
  83. COVID-19: The African Enigma
  84. Prevalence of Onchocerciasis-Associated Epilepsy in Mvolo County, South Sudan: A Door to Door Survey
  85. Vietnamese People’s Well-Being During the COVID-19 Pandemic: An Online Survey
  86. Onchocerciasis Prevalence among Persons with Epilepsy in an Onchocerciasis Hypo-Endemic Area in the Democratic Republic of Congo: A Cross-Sectional Study
  87. Potential Parasitic Causes of Epilepsy in an Onchocerciasis Endemic Area in the Ituri Province, Democratic Republic of Congo
  88. Violence and discrimination among Ugandan residents during the COVID-19 lockdown
  89. Cytokines and Onchocerciasis-Associated Epilepsy, a Pilot Study and Review of the Literature
  90. Adherence to COVID-19 Prevention Measures in the Democratic Republic of the Congo, Results of Two Consecutive Online Surveys
  91. COVID-19 Preventive Behaviours in Cameroon: A Six-Month Online National Survey
  92. Nodding syndrome research revisited
  93. Community perceptions and attitudes regarding epilepsy and disease cost after implementation of a community-based epilepsy treatment program in onchocerciasis-endemic communities in the Democratic Republic of Congo
  94. Impact of COVID-19 on the lives and psychosocial well-being of persons with epilepsy during the third trimester of the pandemic: Results from an international, online survey
  95. Determinants of Modern Contraceptive Methods (MCM) discontinuation among childbearing age women in Kinshasa, Democratic Republic of Congo.
  96. In pursuit of a cure: The plural therapeutic landscape of onchocerciasis-associated epilepsy in Cameroon – A mixed methods study
  97. COVID-19 Vaccine Acceptance in the Democratic Republic of Congo: A Cross-Sectional Survey
  98. Fear and Depression during the COVID-19 Outbreak in Cameroon: A Nation-wide Observational Study
  99. Adherence to COVID-19 Preventive Measures in Mozambique: Two Consecutive Online Surveys
  100. Neuropathological Changes in Nakalanga Syndrome—A Case Report
  101. COVID-19 outbreak in Brazil: adherence to national preventive measures and impact on people’s lives, an online survey
  102. Onchocerca volvulus and epilepsy: A comprehensive review using the Bradford Hill criteria for causation
  103. Adherence to COVID-19 Preventive Measures Prior to Vaccine Interventions: A Meta-Analysis of Online Surveys in Sub-Saharan Africa
  104. Assessment of adherence to public health measures and their impact on the COVID-19 outbreak in Benin Republic, West Africa
  105. Factors associated with adherence to COVID-19 prevention measures in the Democratic Republic of the Congo (DRC): results of an online survey
  106. Nodding syndrome, many questions remain but we can prevent it by eliminating onchocerciasis
  107. Lack of elevated pre-ART elastase-ANCA levels in patients developing TB-IRIS
  108. Effect of Ivermectin Treatment on the Frequency of Seizures in Persons with Epilepsy Infected with Onchocerca volvulus
  109. Case Report: Nakalanga Syndrome Revisited: Long-Term Follow-Up of a Patient Living in Western Uganda, 1994–2018
  110. Ivermectin Treatment Response in Two Rural Villages with a High Prevalence of Onchocerciasis and Epilepsy, Mahenge Tanzania
  111. Onchocerciasis-associated epilepsy an unrecognised important preventable public health problem
  112. Level and Determinants of Adherence to COVID-19 Preventive Measures in the First Stage of the Outbreak in Uganda
  113. Impact of the COVID-19 Pandemic on the Medical Follow-up and Psychosocial Well-Being of People Living With HIV: A Cross-Sectional Survey
  114. Access to healthcare and prevalence of anxiety and depression in persons with epilepsy during the COVID-19 pandemic: A multicountry online survey
  115. Changes in epilepsy burden after onchocerciasis elimination in a hyperendemic focus of western Uganda: a comparison of two population-based, cross-sectional studies
  116. Improving mental health and psychosocial wellbeing in humanitarian settings: reflections on research funded through R2HC
  117. OV16 Seroprevalence among Persons with Epilepsy in Onchocerciasis Endemic Regions: A Multi-Country Study
  118. Violence and Discrimination Among Ugandan Residents During the COVID-19 Lockdown
  119. A call for strengthened evidence on targeted, non-pharmaceutical interventions against COVID-19 for the protection of vulnerable individuals in sub-Saharan Africa
  120. Epilepsy-related stigma and cost in two onchocerciasis-endemic areas in South Sudan: A pilot descriptive study
  121. Vietnamese People’s Well-Being During the COVID-19 Pandemic: An Online Survey
  122. Vietnamese people’s well-being during the COVID-19 pandemic: an online survey 
  123. Preventive behavior of Vietnamese people in response to the COVID-19 pandemic
  124. COVID-19 in Somalia: Adherence to Preventive Measures and Evolution of the Disease Burden
  125. Mass masking as a way to contain COVID-19 and exit lockdown in low- and middle-income countries
  126. Evidence for significant COVID-19 community transmission in Somalia using a clinical case definition
  127. Ivermectin Treatment Response in Onchocerca Volvulus Infected Persons with Epilepsy: A Three-Country Short Cohort Study
  128. COVID-19 outbreak in Brazil: Adherence to national preventive measures and impact on people’s lives
  129. Le français innovant
  130. Comparison of Diagnostic Tests for Onchocerca volvulus in the Democratic Republic of Congo
  131. Dried Blood Microsampling-Based Therapeutic Drug Monitoring of Antiepileptic Drugs in Children With Nodding Syndrome and Epilepsy in Uganda and the Democratic Republic of the Congo
  132. Persons with onchocerciasis-associated epilepsy and nodding seizures have a more severe form of epilepsy with more cognitive impairment and higher levels of Onchocerca volvulus infection
  133. Preventive behavior of Vietnamese people in response to the COVID-19 pandemic
  134. From nodding syndrome to onchocerciasis-associated epilepsy
  135. Focus of Ongoing Onchocerciasis Transmission Close to Bangui, Central African Republic
  136. The Role of the Maridi Dam in Causing an Onchocerciasis-Associated Epilepsy Epidemic in Maridi, South Sudan: An Epidemiological, Sociological, and Entomological Study
  137. Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali
  138. Single versus Multiple Dose Ivermectin Regimen in Onchocerciasis-Infected Persons with Epilepsy Treated with Phenobarbital: A Randomized Clinical Trial in the Democratic Republic of Congo
  139. Meta-analysis of epilepsy prevalence in West Africa and its relationship with onchocerciasis endemicity and control
  140. Urinary N-acetyltyramine-O,β-glucuronide in Persons with Onchocerciasis-Associated Epilepsy
  141. Prevalence and incidence of nodding syndrome and other forms of epilepsy in onchocerciasis-endemic areas in northern Uganda after the implementation of onchocerciasis control measures
  142. Safety of ivermectin during pregnancy
  143. Onchocerca volvulus is not detected in the cerebrospinal fluid of persons with onchocerciasis-associated epilepsy
  144. Single Versus Multiple Dose Ivermectin Regimen in Onchocerciasis-infected Persons with Epilepsy Treated with Phenobarbital: A Randomized Clinical Trial in the Democratic Republic of Congo
  145. Lymphedema in three previously Wuchereria bancrofti-endemic health districts in Mali after cessation of mass drug administration
  146. Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial
  147. Ivermectin use in children below 15 kg: potential benefits for onchocerciasis and scabies elimination programmes
  148. Epilepsy prevention
  149. Nodding Syndrome
  150. Elimination of onchocerciasis in Africa by 2025: an ambitious target requires ambitious interventions
  151. Women with epilepsy in sub–Saharan Africa: A review of the reproductive health challenges and perspectives for management
  152. Emergomyces: The global rise of new dimorphic fungal pathogens
  153. Neuroinflammation and Not Tauopathy Is a Predominant Pathological Signature of Nodding Syndrome
  154. Analysis of the RIMDAMAL trial
  155. Would ivermectin for malaria control be beneficial in onchocerciasis-endemic regions?
  156. Increased cost‐benefit of strengthening onchocerciasis elimination efforts in areas with high onchocerciasis‐associated epilepsy
  157. The efficacy of a brief intervention to reduce alcohol use in persons with HIV in South Africa, a randomized clinical trial
  158. From river blindness to river epilepsy: Implications for onchocerciasis elimination programmes
  159. Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density
  160. Low ivermectin use among 5- to 6-year-old children: observations from door-to-door surveys in onchocerciasis-endemic regions in Africa
  161. Onchocerciasis-associated epilepsy: another piece in the puzzle from the Mahenge mountains, southern Tanzania
  162. Stigma and epilepsy in onchocerciasis-endemic regions in Africa: a review and recommendations from the onchocerciasis-associated epilepsy working group
  163. Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index
  164. Epidemiological evidence concerning the association between onchocerciasis and epilepsy
  165. Increased KLRG1 and PD-1 expression on CD8 T lymphocytes in TB-IRIS
  166. New filovirus disease classification and nomenclature
  167. Impact of 19 years of mass drug administration with ivermectin on epilepsy burden in a hyperendemic onchocerciasis area in Cameroon
  168. Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density
  169. Economic Burden of Epilepsy in Rural Ituri, Democratic Republic of Congo
  170. Comprehensive management of epilepsy in onchocerciasis-endemic areas: lessons learnt from community-based surveys
  171. High prevalence of epilepsy in an onchocerciasis endemic health zone in the Democratic Republic of the Congo, despite 14 years of community-directed treatment with ivermectin: A mixed-method assessment
  172. Integrated seroprevalence-based assessment of Wuchereria bancrofti and Onchocerca volvulus in two lymphatic filariasis evaluation units of Mali with the SD Bioline Onchocerciasis/LF IgG4 Rapid Test
  173. Low prevalence of epilepsy and onchocerciasis after more than 20 years of ivermectin treatment in the Imo River Basin in Nigeria
  174. Nodding syndrome research, lessons learned from the NSETHIO project
  175. Clinical presentations of onchocerciasis-associated epilepsy (OAE) in Cameroon
  176. Intervention for reducing epilepsy-associated stigma
  177. The Effect of Onchocerciasis Elimination on Onchocerciasis-Associated Epilepsy in a Hyper-Endemic Focus of Western Uganda
  178. Effect of TB/HIV Integration on TB and HIV Indicators in Rural Ugandan Health Facilities
  179. Community perceptions of epilepsy and its treatment in an onchocerciasis endemic region in Ituri, Democratic Republic of Congo
  180. Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13 years of ivermectin
  181. High prevalence of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan: A community-based survey
  182. Oral Tecovirimat for the Treatment of Smallpox
  183. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS
  184. The effect of bi-annual community-directed treatment with ivermectin on the incidence of epilepsy in onchocerciasis endemic villages in South Sudan: a study protocol
  185. Factors Influencing the Risk of Becoming Sexually Active Among HIV Infected Adolescents in Kampala and Kisumu, East Africa
  186. Clinical characteristics of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan
  187. The temporal relationship between onchocerciasis and epilepsy: a population-based cohort study
  188. Onchocerca volvulus as a risk factor for developing epilepsy in onchocerciasis endemic regions in the Democratic Republic of Congo: a case control study
  189. Is nodding syndrome in northern Uganda linked to consumption of mycotoxin contaminated food grains?
  190. Opportunistic diseases diminish the clinical benefit of immediate antiretroviral therapy in HIV–tuberculosis co-infected adults with low CD4+ cell counts
  191. Burden of onchocerciasis-associated epilepsy: first estimates and research priorities
  192. Aberrant plasma MMP and TIMP dynamics in Schistosoma - Immune reconstitution inflammatory syndrome (IRIS)
  193. High prevalence of epilepsy in onchocerciasis endemic health areas in Democratic Republic of the Congo
  194. Onchocerciasis associated epilepsy: An important neglected public health problem
  195. Epilepsy caused by onchocerciasis is an important public health problem in Africa
  196. High prevalence of epilepsy in two rural onchocerciasis endemic villages in the Mahenge area, Tanzania, after 20 years of community directed treatment with ivermectin
  197. Factors Associated with Wuchereria bancrofti Microfilaremia in an Endemic Area of Mali
  198. The blackfly vectors and transmission of Onchocerca volvulus in Mahenge, south eastern Tanzania
  199. Synergistic Impact of Training Followed by On-Site Support on HIV Clinical Practice: A Mixed-Design Study in Uganda With Pre/Post and Cluster-Randomized Trial Components
  200. Histological examination of post-mortem brains of children with nodding syndrome
  201. Considerations for Randomized Controlled Trials During Future Filovirus Outbreaks
  202. From river blindness control to elimination: bridge over troubled water
  203. Report of the first international workshop on onchocerciasis-associated epilepsy
  204. Evolution of epilepsy prevalence and incidence in a Tanzanian area endemic for onchocerciasis and the potential impact of community-directed treatment with ivermectin: a cross-sectional study and comparison over 28 years
  205. Molecular tests expedite the diagnosis of multidrug-resistant tuberculosis in childhood
  206. Onchocerciasis-Associated Epilepsy, an Additional Reason for Strengthening Onchocerciasis Elimination Programs
  207. Emergomyces africanus in Soil, South Africa
  208. Neutrophil Activation and Enhanced Release of Granule Products in HIV-TB Immune Reconstitution Inflammatory Syndrome
  209. Molecular detection of airborne Emergomyces africanus, a thermally dimorphic fungal pathogen, in Cape Town, South Africa
  210. Elevated inflammatory cytokines in aqueous cytokine profile in HIV-1 infected patients with cataracts in Uganda
  211. Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and Uganda
  212. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
  213. High Prevalence of Onchocerciasis-Associated Epilepsy in Villages in Maridi County, Republic of South Sudan
  214. High mortality in non-Ebola virus disease cases: need to provide timely and effective care
  215. Attempted molecular detection of the thermally dimorphic human fungal pathogen Emergomyces africanus in terrestrial small mammals in South Africa
  216. Ivermectin Treatment in Patients With Onchocerciasis-Associated Epilepsy: Protocol of a Randomized Clinical Trial
  217. Significant rates of risky sexual behaviours among HIV-infected patients failing first-line ART: A sub-study of the Europe–Africa Research Network for the Evaluation of Second-line Therapy trial
  218. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
  219. The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study
  220. High prevalence of epilepsy in onchocerciasis endemic regions in the Democratic Republic of the Congo
  221. The predicament of patients with suspected Ebola
  222. Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert® MTB/RIF era: a cohort study
  223. Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia
  224. Trends in Prevalence of Advanced HIV Disease at Antiretroviral Therapy Enrollment — 10 Countries, 2004–2015
  225. Early childhood transmission of hepatitis B prior to the first hepatitis B vaccine dose is rare among babies born to HIV-infected and non-HIV infected mothers in Gulu, Uganda
  226. Onchocerciasis-associated epilepsy: From recent epidemiological and clinical findings to policy implications
  227. First HIV prevalence estimates of a representative sample of adult sub-Saharan African migrants in a European city. Results of a community-based, cross-sectional study in Antwerp, Belgium
  228. Relationship Between Time to Initiation of Antiretroviral Therapy and Treatment Outcomes: A Cohort Analysis of ART Eligible Adolescents in Zimbabwe
  229. Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys
  230. Body Mass Index and Waist Circumference in Patients with HIV in South Africa and Associated Socio-demographic, Health Related and Psychosocial Factors
  231. Nodding syndrome: Preventable and treatable
  232. Persons living with HIV infection on antiretroviral therapy also consulting traditional healers: a study in three African countries
  233. AIDS-Related Endemic Mycoses in Western Cape, South Africa, and Clinical Mimics: A Cross-Sectional Study of Adults With Advanced HIV and Recent-Onset, Widespread Skin Lesions
  234. Nodding syndrome, other forms of epilepsy, and the Nakalanga syndrome most likely directly or indirectly caused by Onchocerca volvulus
  235. Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial
  236. Weight status and associated factors among HIV infected people on antiretroviral therapy in rural Dikgale, Limpopo, South Africa
  237. Is Plasmodium Species Parasitemia Really Associated With Increased Survival in Ebola Virus–Infected Patients?
  238. PrEP for African migrants in Europe? A research agenda
  239. Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa
  240. Overlooking the importance of immunoassays – Authors' reply
  241. Effect of On-Site Support on Laboratory Practice for Human Immunodeficiency Virus, Tuberculosis, and Malaria Testing
  242. Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial)
  243. Effectiveness of educational outreach in infectious diseases management: a cluster randomized trial in Uganda
  244. Risk factors for epilepsy in Bas-Uélé Province, Democratic Republic of the Congo: a case–control study
  245. Nodding Syndrome in Onchocerciasis Endemic Areas
  246. Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa
  247. High-risk alcohol use and associated socio-demographic, health and psychosocial factors in patients with HIV infection in three primary health care clinics in South Africa
  248. Added Value of Long-Term Cytokine Release Assays to Detect Mycobacterium tuberculosis Infection in HIV-Infected Subjects in Uganda
  249. Essentials of filoviral load quantification
  250. Prevalence of River Epilepsy in the Orientale Province in the Democratic Republic of the Congo
  251. Nodding syndrome and epilepsy in onchocerciasis endemic regions: comparing preliminary observations from South Sudan and the Democratic Republic of the Congo with data from Uganda
  252. TOGETHER Project to Increase Understanding of the HIV Epidemic Among Sub-Saharan African Migrants: Protocol of Community-Based Participatory Mixed-Method Studies
  253. Implementation and Operational Research
  254. Nodding syndrome—we can now prevent it
  255. Reasons for Missing Antiretroviral Therapy: Results from a Multi-Country Study in Tanzania, Uganda, and Zambia
  256. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea
  257. Reply to “A Word of Caution in Considering the Use of the Lipoarabinomannan Lateral Flow Assay on Cerebrospinal Fluid for Detection of Tuberculous Meningitis”
  258. Temporal trends in death causes in adults attending an urban HIV clinic in Uganda: a retrospective chart review
  259. A Critical Appraisal of the Ideology of Monogamy’s Influence on HIV Epidemiology
  260. Systematic screening for drug-resistant tuberculosis with Xpert® MTB/RIF in a referral hospital in Cambodia
  261. Assessment of cardiovascular risk factors in people with HIV infection treated with ART in rural South Africa: a cross sectional study
  262. Lower Levels of Antiretroviral Therapy Enrollment Among Men with HIV Compared with Women — 12 Countries, 2002–2013
  263. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study
  264. Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings
  265. Effect of Educational Outreach Timing and Duration on Facility Performance for Infectious Disease Care in Uganda: A Trial with Pre-Post and Cluster Randomized Controlled Components
  266. Nodding Syndrome May Be Only the Ears of the Hippo
  267. The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field
  268. Challenges from Tuberculosis Diagnosis to Care in Community-Based Active Case Finding among the Urban Poor in Cambodia: A Mixed-Methods Study
  269. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study
  270. Lower Pre-Treatment T Cell Activation in Early- and Late-Onset Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome
  271. Accuracy of Lipoarabinomannan and Xpert MTB/RIF Testing in Cerebrospinal Fluid To Diagnose Tuberculous Meningitis in an Autopsy Cohort of HIV-Infected Adults
  272. Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case Series
  273. Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda
  274. Behaviour, not mobility, is a risk factor for HIV
  275. La dia-variation en français actuel
  276. Is Urinary Lipoarabinomannan the Result of Renal Tuberculosis? Assessment of the Renal Histology in an Autopsy Cohort of Ugandan HIV-Infected Adults
  277. Malaria Care in Infants Aged under Six Months in Uganda: An Area of Unmet Needs!
  278. Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor–Based Combination Antiretroviral Therapy
  279. Filovirus epidemic in 1956 in Bili, DRC
  280. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study
  281. Large-scale Convalescent Blood and Plasma Transfusion Therapy for Ebola Virus Disease
  282. Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia
  283. Lactating mothers infected with Ebola virus: EBOV RT-PCR of blood only may be insufficient
  284. Is frontloaded sputum microscopy an option in active tuberculosis case finding?
  285. Atypical manifestations of visceral leishmaniasis in patients with HIV in north Ethiopia: a gap in guidelines for the management of opportunistic infections in resource poor settings
  286. Correlates of concurrency among young people in Carletonville, South Africa
  287. Antiretroviral Treatment Program Retention among HIV-Infected Children in the Democratic Republic of Congo
  288. Practice of percutaneous needle autopsy; a descriptive study reporting experiences from Uganda
  289. Antigen-Specific Interferon-Gamma Responses and Innate Cytokine Balance in TB-IRIS
  290. Nodding syndrome since 2012: recent progress, challenges and recommendations for future research
  291. Priorities for Ebola virus disease response in west Africa
  292. Disease diagnosis in primary care in Uganda
  293. Cost-Effectiveness of Socioeconomic Support as Part of HIV Care for the Poor in an Urban Community-Based Antiretroviral Program in Uganda
  294. Needle Autopsy to Establish the Cause of Death in HIV-Infected Hospitalized Adults in Uganda
  295. Nodding syndrome—a new hypothesis and new direction for research
  296. Retention and risk factors for attrition among adults in antiretroviral treatment programmes in Tanzania, Uganda and Zambia
  297. Concentration of Lymph Node Aspirate Improves the Sensitivity of Acid Fast Smear Microscopy for the Diagnosis of Tuberculous Lymphadenitis in Jimma, Southwest Ethiopia
  298. CD4 T-cell activation and reduced regulatory T-cell populations are associated with early development of cataracts among HIV-infected adults in Uganda
  299. Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa
  300. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration
  301. Migration intensity has no effect on peak HIV prevalence: an ecological study
  302. Delays in diagnosis and treatment of pulmonary tuberculosis in Wakiso and Mukono districts, Uganda
  303. A non-synonymous polymorphism in IL-23R Gene (rs1884444) is associated with reduced risk to schistosomiasis-associated Immune Reconstitution Inflammatory Syndrome in a Kenyan population
  304. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe
  305. Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation
  306. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations
  307. Cardiovascular risk factors in a treatment-naïve, human immunodeficiency virus-infected rural population in Dikgale, South Africa
  308. Early Tracking after a Missed Return Visit Reduces the Proportion of Untraceable Patients at a Large HIV Clinic in Kampala, Uganda
  309. Two year mortality and associated factors in a cohort of children from rural Uganda
  310. Community-Based Active Tuberculosis Case Finding in Poor Urban Settlements of Phnom Penh, Cambodia: A Feasible and Effective Strategy
  311. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study
  312. Patients who return to care after tracking remain at high risk of attrition: experience from a large HIV clinic, Uganda
  313. Health Outcomes of Infants in a PMTCT Program in Kinshasa
  314. Deteriorating renal function and clinical outcomes in HIV-positive persons
  315. Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe
  316. Effect of Integrated Capacity-Building Interventions on Malaria Case Management by Health Professionals in Uganda: A Mixed Design Study with Pre/Post and Cluster Randomized Trial Components
  317. The Association between Female Genital Cutting and Spousal HCV Infection in Egypt
  318. The role of monocytes in the development of Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome
  319. LPS-Binding Protein and IL-6 Mark Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome in HIV Patients
  320. Does the CHER trial open up new therapeutic perspectives?
  321. Increase in numbers and proportions of review articles in Tropical Medicine, Infectious Diseases, and oncology
  322. Evaluation of the 2007 WHO guideline to diagnose smear negative tuberculosis in an urban hospital in Ethiopia
  323. Predictors of Mortality among Tuberculosis/HIV-Coinfected Persons in Southwest Ethiopia
  324. Acceptability of HIV self-testing: a systematic literature review
  325. Implementation of tuberculosis infection control in health facilities in Mukono and Wakiso districts, Uganda
  326. Burden of tuberculosis disease among adolescents in a rural cohort in Eastern Uganda
  327. Factors before enrolment are associated with being removed from a Pharmacy-only Refill Programme at a large urban HIV/AIDS clinic, Uganda
  328. Partner-concurrency associated with herpes simplex virus 2 infection in young South Africans
  329. Modulation of the complement system in monocytes contributes to tuberculosis-associated immune reconstitution inflammatory syndrome
  331. Antiretrovirals During Pregnancy: A Note of Caution
  332. Determinants of generalized herpes simplex virus-2 epidemics: the role of sexual partner concurrency
  333. Peak HIV prevalence: a useful outcome variable for ecological studies
  334. Change in quality of life: a follow up study among patients with HIV infection with and without TB in Ethiopia
  335. Antiretroviral Drug Resistance Profiles and Response to Second-Line Therapy Among HIV Type 1-Infected Ugandan Children
  336. Birds of a feather: homophily and sexual network structure in sub-Saharan Africa
  337. Hyperlactatemia and concurrent use of antiretroviral therapy among HIV infected patients in Uganda
  338. Ellipse et fragment
  339. Clinical Manifestations and Case Management of Ebola Haemorrhagic Fever Caused by a Newly Identified Virus Strain, Bundibugyo, Uganda, 2007–2008
  340. Design of a cluster randomized trial assessing integrated infectious diseases training and on-site support for midlevel practitioners in Uganda
  341. Response to Antiretroviral Therapy of HIV Type 1-Infected Children in Urban and Rural Settings of Uganda
  342. Determinants of male involvement in maternal and child health services in sub-Saharan Africa: a review
  343. Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia
  344. Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years?
  345. Low prevalence of vitamin D deficiency in Ugandan HIV-infected patients with and without tuberculosis
  346. Strong association between point-concurrency and national peak HIV prevalence
  347. Utilization of HIV and Tuberculosis Services by Health Care Workers in Uganda: Implications for Occupational Health Policies and Implementation
  348. The efficacy of a brief intervention to reduce alcohol misuse in patients with HIV in South Africa: study protocol for a randomized controlled trial
  349. Depression and Posttraumatic Stress Disorder Among HIV-Infected Gambians on Antiretroviral Therapy
  350. Corticosteroid-modulated Immune Activation in the Tuberculosis Immune Reconstitution Inflammatory Syndrome
  351. What Is the Optimal First Line Antiretroviral Therapy in Resource-Limited Settings?
  352. The Role of Raltegravir in the Treatment of HIV-2 Infections: Evidence from a Case Series
  353. Retention in a NGO Supported Antiretroviral Program in the Democratic Republic of Congo
  354. Tuberculosis lymphadenitis in Southwest Ethiopia: a community based cross-sectional study
  355. Sub-Optimal Vitamin B-12 Levels among ART-Naïve HIV-Positive Individuals in an Urban Cohort in Uganda
  356. Clinical Spectrum, Risk Factors and Outcome of Immune Reconstitution Inflammatory Syndrome in Patients with Tuberculosis–HIV Coinfection
  357. Corticosteroid Therapy, Vitamin D Status, and Inflammatory Cytokine Profile in the HIV-Tuberculosis Immune Reconstitution Inflammatory Syndrome
  358. Return to Normal Life After AIDS as a Reason for Lost to Follow-up in a Community-Based Antiretroviral Treatment Program
  359. Predictors of condom use and refusal among the population of Free State province in South Africa
  360. Strategies for Optimizing Clinic Efficiency in a Community-Based Antiretroviral Treatment Programme in Uganda
  361. PhDs: Adapt training for developing world
  362. Socioeconomic Support Reduces Nonretention in a Comprehensive, Community-Based Antiretroviral Therapy Program in Uganda
  363. An Autopsy Study Describing Causes of Death and Comparing Clinico-Pathological Findings among Hospitalized Patients in Kampala, Uganda
  364. Prevalence of pulmonary TB and spoligotype pattern of Mycobacterium tuberculosis among TB suspects in a rural community in Southwest Ethiopia
  365. A Randomized Controlled Trial to Evaluate the Effectiveness of a Board Game on Patients' Knowledge Uptake of HIV and Sexually Transmitted Diseases at the Infectious Diseases Institute, Kampala, Uganda
  366. A Tale Of Two Epidemics Within TWO Countries
  367. Predictors of antiretroviral treatment-associated tuberculosis in Ethiopia: a nested case-control study
  368. Interventions to reduce mortality in sub-Saharan Africa among HIV-infected adults not yet on antiretroviral therapy
  369. Immune Reconstitution Inflammatory Syndrome in HIV/AIDS
  370. Urinary Lipoarabinomannan as Predictor for the Tuberculosis Immune Reconstitution Inflammatory Syndrome
  371. Filovirus Hemorrhagic Fever Outbreak Case Management: A Review of Current and Future Treatment Options
  372. The immune reconstitution inflammatory syndrome related to HIV co-infections: a review
  373. Antiretroviral treatment in the private sector in Namibia
  374. Incidence and Predictors of Mortality and the Effect of Tuberculosis Immune Reconstitution Inflammatory Syndrome in a Cohort of TB/HIV Patients Commencing Antiretroviral Therapy
  375. Tuberculosis in human immunodeficiency virus infected Ugandan children starting on antiretroviral therapy
  376. Association of haptoglobin phenotypes with the development of Kaposi’s sarcoma in HIV patients
  377. Electronic Medical Records and Same Day Patient Tracing Improves Clinic Efficiency and Adherence to Appointments in a Community Based HIV/AIDS Care Program, in Uganda
  378. Reducing mortality from HIV infection and tuberculosis
  379. Tuberculosis knowledge, attitudes and health-seeking behaviour in rural Uganda
  380. Sexual Satisfaction Among Men Living with HIV in Europe
  381. Autopsy acceptance rate and reasons for decline in Mulago Hospital, Kampala, Uganda
  382. Proposal to Adjust the WHO Clinical Staging System
  383. Cured of fear of flying
  384. Male partner voluntary counselling and testing associated with the antenatal services in Kinshasa, Democratic Republic of Congo: a randomized controlled trial
  385. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort
  386. Tuberculosis drug resistance testing by molecular methods: Opportunities and challenges in resource limited settings
  387. Antiretroviral Treatment-Associated Tuberculosis in a Prospective Cohort of HIV-Infected Patients Starting ART
  389. Thoraco-abdominal Wall Reconstruction after Surgical Debulking of a Giant Retroperitoneal Liposarcoma: a Case Report
  390. Body Weight Changes and Clinical Outcome in Adults on Antiretroviral Therapy in Countries With Limited Resources
  391. The immune reconstitution inflammatory syndrome and antiretroviral therapy
  392. Nutritional Supplementation in HIV‐Infected Individuals Can Be Beneficial in Certain Patient Groups
  393. Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin
  394. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions
  395. Incidence and risk factors associated with lost to follow-up in a Belgian cohort of HIV-infected patients treated with highly active antiretroviral therapy
  396. Challenges in the diagnosis of meningitis in low-resource settings
  397. Knowledge, Health Seeking Behavior and Perceived Stigma towards Tuberculosis among Tuberculosis Suspects in a Rural Community in Southwest Ethiopia
  398. Sexual Protection Behavior in HIV-Positive Gay Men: Testing a Modified Information-Motivation-Behavioral Skills Model
  399. ART in low-resource settings: how to do more with less
  400. Alcohol and Antiretroviral Adherence? What About Africa?
  401. Common mental disorders in TB/HIV co-infected patients in Ethiopia
  402. Prejudice and misconceptions about tuberculosis and HIV in rural and urban communities in Ethiopia: a challenge for the TB/HIV control program
  403. Mirror, mirror on the wall: the face of HIV + women in Europe today
  404. Buruli Ulcer Lesions in HIV-Positive Patient
  405. Predictors of HIV Testing among Patients with Tuberculosis in North West Ethiopia: A Case-Control Study
  406. The International Index of Erectile Function: Development of an Adapted Tool for Use in HIV-Positive Men Who Have Sex with Men
  407. Role of the CD4 count in HIV management
  408. The Prevalence and Causes of Visual Loss Among HIV-Infected Individuals in Uganda
  409. Update on the efficacy, effectiveness and safety of artemether–lumefantrine combination therapy for treatment of uncomplicated malaria
  410. “It's Better Not To Know”: Perceived Barriers to HIV Voluntary Counseling and Testing among Sub-Saharan African Migrants in Belgium
  411. Tuberculosis and HIV co-infection: its impact on quality of life
  412. Provider-initiated HIV testing for paediatric inpatients and their caretakers is feasible and acceptable
  413. An Algorithm to Optimize Viral Load Testing in HIV-Positive Patients With Suspected First-Line Antiretroviral Therapy Failure in Cambodia
  414. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia
  415. Pediatric HIV: new opportunities to treat children
  416. Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?
  417. HIV-1-Infected Individuals Traveling to Malaria Endemic Areas
  418. Initiating antiretroviral treatment in a resource-constrained setting: does clinical staging effectively identify patients in need?
  419. Successful Treatment of Psoriasis-like Lesions in HIV Infected Patients in Uganda with Chloroquine
  420. Substituting tenofovir for stavudine in resource-limited settings: there are challenges ahead
  421. Coping with TB immune reconstitution inflammatory syndrome
  422. Response to “Case of Yellow Fever Vaccine–Associated Viscerotropic Disease with Prolonged Viremia, Robust Adaptive Immune Responses, and Polymorphisms in CCR5 and RANTES Genes”
  423. Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria
  424. Impact of HIV-1 Infection on the Hematological Recovery After Clinical Malaria
  425. Improvement of the patient flow in a large urban clinic with high HIV seroprevalence in Kampala, Uganda
  426. Clinical presentation and aetiologies of acute or complicated headache among HIV-seropositive patients in a Ugandan clinic
  427. Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome?
  428. Mortality and Associated Factors After Initiation of Pediatric Antiretroviral Treatment in the Democratic Republic of the Congo
  429. Three-Year Outcome Data of Second-Line Antiretroviral Therapy in Ugandan Adults: Good Virological Response but High Rate of Toxicity
  430. Biology and Natural History of Acquired Immunodeficiency Syndrome
  431. Fatal and Fulminant Infections
  432. A Visual Dosing Aid for First-line Pediatric Antiretroviral Treatment in Resource-poor Settings
  433. Differences in perceptions on sexual and reproductive health between service providers and people living with HIV: A qualitative elicitation study
  434. Episodic Antiretroviral Therapy Increases HIV Transmission Risk Compared With Continuous Therapy: Results of a Randomized Controlled Trial
  435. Universal access to HIV care: pitfalls and the way forward
  436. Drug-resistant TB and HIV in resource-limited settings: what TB/HIV programmes can learn from each other
  437. Fever After a Stay in the Tropics: Clinical Spectrum and Outcome in HIV-Infected Travelers and Migrants
  438. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings
  439. The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance
  440. HIV education for health-care professionals in high prevalence countries: time to integrate a pre-service approach into training
  441. Immune restoration disease
  442. Determination of the Incidence of Tuberculosis in Low‐Income Countries
  443. HIV care and treatment for children in resource-limited settings
  444. Pediatric HIV infection: the state of antiretroviral therapy
  445. Sexual risk reduction needs of adolescents living with HIV in a clinical care setting
  446. Computed CD4 percentage as a low-cost method for determining pediatric antiretroviral treatment eligibility
  447. Increased Risk for Entamoeba histolytica Infection and Invasive Amebiasis in HIV Seropositive Men Who Have Sex with Men in Taiwan
  448. Evaluation of the GIDEON Expert Computer Program for the Diagnosis of Imported Febrile Illnesses
  449. Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome?
  450. Marburg Hemorrhagic Fever in Durba and Watsa, Democratic Republic of the Congo: Clinical Documentation, Features of Illness, and Treatment
  451. Co-trimoxazole prophylaxis in tropical countries in the era of highly active antiretroviral therapy: do we know enough?
  452. Current Hemoglobin Levels Are More Predictive of Disease Progression Than Hemoglobin Measured at Baseline in Patients Receiving Antiretroviral Treatment for HIV Type 1 Infection
  453. Predictors of Long-Term Viral Failure Among Ugandan Children and Adults Treated With Antiretroviral Therapy
  454. Pulmonary cystic disease in HIV positive individuals in the Democratic Republic of Congo: three case reports
  455. Sexual dysfunction in HIV-positive men is multi-factorial: A study of prevalence and associated factors
  456. Vena cava inferior thrombosis detected by venous hum: a case report
  457. Lessons Learned From 2 Patients With Multidrug-Resistant HIV-1 Infection Successfully Treated With a Darunavir-Containing Antiretroviral Treatment Regimen
  458. When to switch for antiretroviral treatment failure in resource-limited settings?
  460. Quality of Life in HIV Clinical Trials: Why Sexual Health Must Not Be Ignored
  461. Selective ambulatory management of imported falciparum malaria: a 5-year prospective study
  462. Tuberculosis in resource poor countries
  463. Assessment of the patient flow at the infectious diseases institute out-patient clinic, Kampala, Uganda
  464. Fever After a Stay in the Tropics
  465. HIV‐1 Immune Suppression and Antimalarial Treatment Outcome in Zambian Adults with Uncomplicated Malaria
  466. Remote consultations and HIV/AIDS continuing education in low-resource settings
  467. Réponse des auteurs
  468. Marburg Hemorrhagic Fever Associated with Multiple Genetic Lineages of Virus
  469. Etiology and Outcome of Fever After a Stay in the Tropics
  470. Authors' reply
  471. The Added Value of a CD4 Count to Identify Patients Eligible for Highly Active Antiretroviral Therapy Among HIV-Positive Adults in Cambodia
  472. HIV Eosinophilic Folliculitis in Uganda
  474. Infectious Mononucleosis–Like Syndromes in Febrile Travelers Returning From the Tropics
  475. Unexpected improvement of sexual dysfunction during atazanavir therapy
  476. Imported Katayama fever: Clinical and biological features at presentation and during treatment
  477. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins
  479. Reply to Lawn and Wood
  480. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries
  481. Mycobacterium-associated immune reconstitution disease: macrophages running wild?
  482. Review editorial: Prevention of tuberculosis in resource-poor countries with increasing access to highly active antiretroviral treatment
  483. Response to ‘Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?’ AIDS, 22 July 2005
  484. Pulmonary Sporothrix schenckii Infection in a HIV Positive Child
  485. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk
  486. Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time
  487. Corrélations anatomo-biologiques dans un cas de fièvre jaune importé de Gambie
  488. Free Antiretrovirals Must Not Be Restricted Only to Treatment-Naive Patients
  489. Palliative care in sub-Saharan Africa
  490. Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium
  491. Rolling Out Antiretrovirals in Africa: There Are Still Challenges Ahead
  492. Changes in Human Immunodeficiency Virus Type 1 Fitness and Genetic Diversity during Disease Progression
  494. Risk factors for and types of oesophageal cancer
  495. Merkel cell carcinoma and multiple basal cell carcinoma in an African albino woman with HIV infection
  496. Efavirenz-Associated Stevens-Johnson Syndrome
  497. Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection
  498. Five-year immunological outcome of highly active antiretroviral treatment in a clinical setting: results from a single HIV treatment centre
  499. The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment
  500. Families affected by HIV: Parents’ and children's characteristics and disclosure to the children
  501. Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe
  502. Organisation of health care during an outbreak of Marburg haemorrhagic fever in the Democratic Republic of Congo, 1999
  503. Development, Evaluation, and Validation of an Oligonucleotide Probe Hybridization Assay To Subtype Human Immunodeficiency Virus Type 1 Circulating Recombinant Form CRF02_AG
  504. Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients
  505. Mixed Arterial and Venous Thromboembolism in a Person with HIV Infection
  506. Risk Factors for Marburg Hemorrhagic Fever, Democratic Republic of the Congo
  507. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir
  508. The use of complementary and alternative medicine by persons with HIV infection in Europe
  509. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases
  510. Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment
  511. Current thinking on the management of tuberculosis
  512. Editorial: Giving antiretrovirals in the peripartum period to prevent mother-to-child HIV transmission in low-income countries: only a short-term stopgap measure
  513. Multiple Tuberculous Brain Abscesses in an HIV-Infected Patient Successfully Treated with HAART and Antituberculous Treatment
  514. Human and simian immunodeficiency virus-infected chimpanzees do not have increased intracellular levels of ?-chemokines in contrast to infected humans
  515. Highly active antiretroviral treatment in countries with very limited resources: do we have cheaper alternatives?
  516. HIV and sexual dysfunction
  519. Regional and temporal changes in AIDS in Europe before HAART
  520. A Belgian Traveler Who Acquired Yellow Fever in The Gambia
  521. Short communication: A cluster of Marburg virus disease involving an infant*
  522. Financial situation of people living with HIV in Europe
  526. Self-reported signs of lipodystrophy by persons living with HIV infection
  527. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression
  528. Management of co-infection with HIV and TB
  529. Do Patents Prevent Access to Drugs for HIV in Developing Countries?
  530. Neuropsychiatric reaction induced by clarithromycin
  531. A Multidrug, Including Voriconazole, Resistant Oral Candida Infection in an AIDS Patient Effectively Treated with Echinocandin
  532. Rheumatological complications associated with the use of indinavir and other protease inhibitors
  533. Direct costs of health care for HIV/AIDS patients in Belgium
  534. Imported case of confirmed yellow fever detected in Belgium
  535. Diagnosis at first glance: nodular hepatic lesions in persons with AIDS
  536. Hospital based clinical surveillance for dengue haemorrhagic fever in Bandung, Indonesia 1994–1995
  537. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment
  538. Hospital services for people with HIV infection in Flanders: Patients' satisfaction
  539. Predominance of HIV Type 1 Subtype G among Commercial Sex Workers from Kinshasa, Democratic Republic of Congo
  540. Book: HIV
  541. Antiretroviral treatments used among adults with HIV infection in Europe
  542. Participants in HIV clinical trials in Europe
  543. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: A partial solution to Africa's HIV/AIDS problem?
  544. T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB)
  545. Utilization of healthcare services by people living with HIV/AIDS in Europe
  546. A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression
  547. AIDS caused by HIV1 and HIV2 infection: are there clinical differences? Results of AIDS surveillance 1986-97 at Fann Hospital in Dakar, Senegal
  548. Natural Residues versus Antiretroviral Drug-Selected Mutations in HIV Type 1 Group O Reverse Transcriptase and Protease Related to Virological Drug Failurein Vivo
  549. Near Full-Length Genome Analysis of HIV Type 1 CRF02.AG, Subtype C and CRF02.AG Subtype G Recombinants
  550. Curly Hair and Lipodystrophy as a Result of Highly Active Antiretroviral Treatment?
  552. Impact of New Developments in Antiretroviral Treatment on AIDS Prevention and Care in Resource-Poor Countries
  553. Viewpoint: Filovirus haemorrhagic fever outbreaks: much ado about nothing?
  554. Cutaneous Ulcer Caused by Mycobacterium avium and Recurrent Genital Herpes After Highly Active Antiretroviral Therapy
  555. Ebola Haemorrhagic Fever – a Review
  556. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates
  557. Multicentric Castleman’s Disease in 2 Patients with HIV Infection, Unresponsive to Antiviral Therapy
  558. Q Fever After A Journey In Syria: A Diagnosis Suggested by Bone Marrow Biopsy
  559. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy
  560. Unusual cutaneous lesions in two patients with visceral leishmaniasis and HIV infection
  561. Euthanasia and End-of-Life Care
  562. Treatment and Prevention of Multidrug-Resistant Tuberculosis
  563. Sequence Note: HIV Type 1 C2V3 env Diversity among Belgian Individuals
  564. Recurrence of blackwater fever: triggering of relapses by different antimalarials
  565. Painful hyperaesthesia caused by protease inhibitors?
  566. Deafness Caused by Didanosine
  567. Cross-sectional study of oral Candida carriage in a human immunodeficiency virus (HIV)-seropositive population: predisposing factors, epidemiology and antifungal susceptibility
  568. Deafness caused by didanosine
  569. Splenic Rupture as a Complication ofP. FalciparumMalaria After Residence in The Tropics. Report of Two Cases.
  570. Eosinophilia in Patients Infected with Human Immunodeficiency Virus
  571. Histoplasma Capsulatum Infection in Three AIDS Patients Living in Africa
  572. Bordetella pertussis as a cause of chronic respiratory infection in an AIDS patient
  573. HIV diagnosis delay in Antwerp, Belgium.
  574. The Interleukin-2 Receptor Subunit Expression and Function on Peripheral Blood Lymphocytes from HIV-Infected and Control Persons
  575. Surveillance case definition for AIDS in resource-poor countries
  576. Priorities for HIV testing in developing countries?
  577. Bibliographie
  578. Imported Relapsing Fever in European Tourists
  579. Orthostatic hypotension in HIV infection in Africa
  580. Pulmonary T-Cell Lymphoma in a Patient with the Acquired Immunodeficiency Syndrome
  581. The Prevalence of Hairy Leukoplakia in HIV Seropositive and HIV Seronegative Immunocompromised Patients
  582. Psoriasis regression in terminal AIDS
  583. An African Patient With Aids And Linitis Plastica
  584. For debate. AIDS surveillance in Africa: a reappraisal of case definitions.
  585. Increased Mortality and Tuberculosis Treatment Failure Rate among Human Immunodeficiency Virus (HIV) Seropositive Compared with HIV Seronegative Patients with Pulmonary Tuberculosis Treated with “Standard” Chemotherapy in Kinshasa, Zaire
  586. Seroconversion Rate, Mortality, and Clinical Manifestations Associated with the Receipt of a Human Immunodeficiency Virus-Infected Blood Transfusion in Kinshasa, Zaire
  587. Treatment for Kaposi's sarcoma in HIV-negative, non-homosexual men
  588. Mefloquine-induced Stevens-Johnson syndrome
  589. The association between malaria, blood transfusions, and HIV seropositivity in a pediatric population in Kinshasa, Zaire
  590. BCG Vaccine Abscesses Are Unrelated to HIV Infection
  591. Association Between HTLV-III/ LAV Infection and Tuberculosis in Zaire
  592. Carcinoid Heart Disease
  593. Carcinoid heart disease
  594. Opportunistic Infections